Skip to content

Psilocybin for depression

Studies whose primary subject is both Psilocybin and Depression, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, Depression, major depressive disorder, then ranked by relevance.

Across randomized and open-label trials, psilocybin given with psychological support produces rapid, large reductions in depressive symptoms, with response and remission often persisting for weeks to months and, in some cohorts, up to 6-12 months. The strongest controlled evidence shows a single 25 mg dose beats a 1 mg control at 3 weeks in treatment-resistant depression, while a head-to-head trial found no significant difference from escitalopram at 6 weeks. Caveats are substantial: many studies are small, open-label, or unblinded, durability beyond a few months is uncertain, and trials enroll highly selected patients.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial 2016 RCT 51 Supports High-dose psilocybin produced large decreases in depressed mood and anxiety, with about 80% showing clinically significant improvement sustained at 6 months.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016 RCT (crossover) 29 Supports Single-dose psilocybin with psychotherapy produced rapid, substantial improvements in anxiety and depression, with roughly 60-80% retaining clinically significant reductions at 6.5 months.
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016 open-label feasibility trial 12 Supports Two psilocybin doses were well tolerated and associated with marked reductions in depressive symptoms at 1 week and 3 months.
Trial of Psilocybin versus Escitalopram for Depression 2021 RCT No effect No significant difference in antidepressant effect between psilocybin and escitalopram on the primary week-6 outcome, though uncorrected secondary outcomes generally favored psilocybin.
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder 2020 RCT (waiting-list controlled) 24 Supports Psilocybin with supportive psychotherapy produced large, significant reductions in depression severity versus a waiting list, with 71% response at week 1 and 54% remission at week 4.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. 2022 phase 2 double-blind RCT 233 Supports A single 25 mg dose significantly reduced MADRS scores at week 3 versus a 1 mg control (difference -6.6), while 10 mg did not differ from control; sustained response at 12 weeks was not clearly supported.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2017 open-label trial 20 Supports Two psilocybin doses produced large reductions in depressive symptoms (Cohen's d 2.2-2.3 early) that remained significant at 3 and 6 months (d 1.5 and 1.4).
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression 2018 clinical trial (secondary analysis) 20 Supports Oceanic boundlessness and dread of ego dissolution during the psilocybin session predicted improvement in depressive symptoms at 5 weeks.
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. 2017 observational cohort 19 Supports All 19 patients showed decreased depressive symptoms at 1 week and 47% met response criteria at 5 weeks, with post-treatment amygdala blood flow and network connectivity changes correlating with symptom reduction.
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression 2017 qualitative 20 Supports Patients described shifts from disconnection to connection and from avoidance to acceptance, and felt psilocybin encouraged these processes more than conventional treatments.
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019 integrative review Supports Reviews evidence that classic psychedelics, including psilocybin, show promise as therapeutics for psychological distress, depression, and addiction.
Single-Dose Psilocybin Treatment for Major Depressive Disorder 2023 phase 2 RCT 104 Supports A single 25 mg dose significantly reduced depressive symptoms and functional disability versus niacin placebo through 43 days, without serious adverse events.
Increased global integration in the brain after psilocybin therapy for depression. 2022 open-label trial plus phase 2 RCT Supports Antidepressant response to psilocybin was rapid and sustained and correlated with decreased brain network modularity, whereas escitalopram response was milder without such changes.
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up 2022 randomized waiting-list controlled follow-up 27 Supports Large reductions in depression scores persisted through 12 months (Cohen's d 2.0-2.6), with 75% response and 58% remission at 12 months and no serious related adverse events.
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies 2020 systematic review 188 Supports Psychedelic-assisted therapy showed feasibility, safety, and promising early efficacy for depression and anxiety, with effects often lasting weeks to months after 1-3 sessions.
Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability 2026 structured narrative review Mixed Concludes psilocybin with psychological support has short-term antidepressant activity, but notes one phase 3 trial met its week-3 endpoint while another missed its week-6 response hypothesis, leaving specific drug effect and durability uncertain.
The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review 2026 narrative review Supports Argues that psilocybin shows therapeutic potential for depression, anxiety, and pain, with proposed mechanisms involving inflammation, the default mode network, and mystical experiences.
Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression. 2026 observational cross-sectional 6793 Mixed Past-year psilocybin use was not associated with conventional mental health treatment utilization but was associated with greater perceived unmet treatment need (52.0% vs 33.9%).
Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial 2026 qualitative 9 Supports Therapists viewed psilocybin treatment as beneficial for psychotherapy and the psychedelic experience as facilitating therapeutic processes, while noting it is undetermined whether psychotherapeutic support is essential.
Mystical Experiences Mediate the Effects of Psilocybin-Assisted Psychotherapy + Mindfulness-Based Stress Reduction on Trait Mindfulness and Depression Symptoms: Mechanistic Results from a Randomized Controlled Trial 2026 RCT 25 Supports Adding group psilocybin-assisted therapy to MBSR produced greater mindfulness gains than MBSR alone at 2 weeks, with mystical experience intensity showing indirect effects on mindfulness and depressive symptom change.
Psilocybin for Anhedonia in Unipolar and Bipolar Depression: A Systematic Review of Clinical and Preclinical Evidence 2026 systematic review 274 Supports Psilocybin-assisted psychotherapy was consistently associated with reduced anhedonia, with two RCTs (pooled n=274) showing greater improvement than control or comparator groups, though small samples and inconsistent measurement limit interpretation.
Connectedness as a Mechanism of Change in Psilocybin-Assisted Cognitive Behavioral Therapy for Major Depressive Disorder 2026 open-label trial (secondary analysis) 15 Mixed Connectedness rose significantly from baseline to post-treatment but was not sustained at 3 months, and greater increases predicted improved depressive and functioning outcomes at follow-up.
EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW 2026 review Supports Concludes psilocybin with psychological support produces rapid, clinically significant symptom reductions with efficacy at least comparable to SSRIs and often faster onset, while calling for large long-term trials.
Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders 2026 secondary analysis of clinical trial 10 Supports Mean MADRS scores fell from 30.4 to 22.3 at 6 months and suicidal ideation item from 3.2 to 1.2, with substantial between-person heterogeneity and no serious adverse events.
Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review 2026 narrative review Supports Finds both psilocybin and ayahuasca produce rapid symptom reductions, with psilocybin having more robust evidence for sustained effects, but argues strict selection, blinding difficulties, and small samples limit generalizability.

Points of agreement

  • Multiple randomized and open-label trials report rapid, large reductions in depressive symptoms after one or two psilocybin sessions with psychological support.
  • Benefits often persist for weeks to months, with several cohorts showing response or remission at 6-12 months.
  • The intensity or quality of the acute psychedelic/mystical experience is repeatedly reported to predict or mediate symptom improvement.
  • Adverse events are generally described as mild to moderate and transient in supervised settings.
  • Reviewers consistently note that trials enroll highly selected patients and that blinding is difficult.

Conflicts

  • One head-to-head RCT found no significant difference from escitalopram on the primary week-6 outcome, while reviews describe psilocybin efficacy as at least comparable to or faster than SSRIs.
  • The large phase 2 dose-finding trial supported week-3 response and remission but not clearly sustained response at 12 weeks, whereas smaller open-label and follow-up studies report durable effects up to 12 months.
  • A structured review notes one phase 3 trial met its primary endpoint while another missed its week-6 response hypothesis, leaving the specific drug effect in question.
  • Connectedness increased post-treatment but was not sustained at 3 months in one analysis, contrasting with reports of durable symptom benefit.

Gaps

  • Durability beyond 6-12 months and optimal retreatment strategy are unresolved.
  • Blinding is difficult to maintain, and expectancy effects may inflate open-label and self-report findings.
  • Sample sizes in most trials are small, and several key studies lack control groups.
  • Whether psychological support is an essential component and what its optimal structure is remains undetermined.
  • Populations are highly selected, excluding comorbidities, high suicide risk, and polypharmacy, limiting real-world generalizability.
  • Dose-response is incompletely characterized, and the specific drug effect versus placebo and psychotherapy contribution is uncertain.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin for depression?
  • Multiple randomized and open-label trials report rapid, large reductions in depressive symptoms after one or two psilocybin sessions with psychological support.
  • Benefits often persist for weeks to months, with several cohorts showing response or remission at 6-12 months.
  • The intensity or quality of the acute psychedelic/mystical experience is repeatedly reported to predict or mediate symptom improvement.
  • Adverse events are generally described as mild to moderate and transient in supervised settings.
  • Reviewers consistently note that trials enroll highly selected patients and that blinding is difficult.
Where do studies on psilocybin for depression conflict?
  • One head-to-head RCT found no significant difference from escitalopram on the primary week-6 outcome, while reviews describe psilocybin efficacy as at least comparable to or faster than SSRIs.
  • The large phase 2 dose-finding trial supported week-3 response and remission but not clearly sustained response at 12 weeks, whereas smaller open-label and follow-up studies report durable effects up to 12 months.
  • A structured review notes one phase 3 trial met its primary endpoint while another missed its week-6 response hypothesis, leaving the specific drug effect in question.
  • Connectedness increased post-treatment but was not sustained at 3 months in one analysis, contrasting with reports of durable symptom benefit.
What is still unknown about psilocybin for depression?
  • Durability beyond 6-12 months and optimal retreatment strategy are unresolved.
  • Blinding is difficult to maintain, and expectancy effects may inflate open-label and self-report findings.
  • Sample sizes in most trials are small, and several key studies lack control groups.
  • Whether psychological support is an essential component and what its optimal structure is remains undetermined.
  • Populations are highly selected, excluding comorbidities, high suicide risk, and polypharmacy, limiting real-world generalizability.
  • Dose-response is incompletely characterized, and the specific drug effect versus placebo and psychotherapy contribution is uncertain.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin for depression, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin for depression or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

509 articles · 220 from the last two years · 53,190 participants across 195 studies reporting sample size

Common study designs

review 120 narrative review 15 systematic review 47 randomized controlled trial 43 systematic review and meta-analysis 20

Research volume by year

Compare topics →

507 studies whose primary subject is psilocybin for depression since 2014

Studies about psilocybin for depression per year, 2014 to 2026, peaking at 111 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 100 200 2015 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin for depression per year, 2014 to 2026, peaking at 111 in 2026
Year Studies
2014 1
2015 1
2016 9
2017 8
2018 5
2019 7
2020 16
2021 44
2022 47
2023 85
2024 73
2025 100
2026 111

Research

Synthesize the evidence →

Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences November 10, 2026 Lydia Belinger, Flora Moujaes, Robin von Rotz et al.

Psychedelic-assisted therapy, particularly with psilocybin, is increasingly proposed as a treatment for major depressive disorder, yet the neural and psychological mechanisms underlying its effects remain under investigation. In a randomized, double-blind, placebo-controlled clinical trial, individuals diagnosed with major depressive disorder received a single, moderate dose of psilocybin...

DOI: 10.1098/rstb.2025.0168 (opens in new tab) Full text (opens in new tab) Depression Psilocybin Psychedelic-assisted therapy Self-concept +1

Psilocybin as a novel drug in the treatment of major depressive disorder: a systematic review

Medical Science October 30, 2026 Jakub Magdziak, Oliwia Borowska, Eliza Mędrek et al.

Major depressive disorder remains one of the most common and debilitating psychiatric disorders in the global population, with a significant number of patients not responding adequately to traditional antidepressant treatments.As such, the need for new methods has prompted studies exploring the use of psychedelic medicines, such as psilocybin, which is a serotonergic psychedelic drug produced...

DOI: 10.54905/disssi.v30i176.e201ms3896 (opens in new tab) Full text (opens in new tab)

Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.

Journal of Affective Disorders October 30, 2026 Andrew M Novick, Tiffany M Love, Rachel L Johnson et al.

Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear. To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD. In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg)...

DOI: 10.1016/j.jad.2026.122676 (opens in new tab) Full text (opens in new tab) Psilocybin Treatment-resistant depression Anhedonia Randomized controlled trial

Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial

medRxiv October 29, 2026 Ceyda Sayalı, Eli Weisman, Frederick Streeter Barrett preprint

Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the willingness to exert control rather than the ability to do so. We tested both...

DOI: 10.64898/2026.10.27.26366630 (opens in new tab) Full text (opens in new tab)

Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.

Psychopharmacology October 26, 2026 Aline Frick, Grace Blest‐hopley, Manesh Girn et al.

Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple...

DOI: 10.1007/s00213-026-07177-7 (opens in new tab) Full text (opens in new tab) Anxiety Major depressive disorder Psilocybin Anhedonia +3

Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability

Therapeutics October 19, 2026 Lukasz Szarpak, Michal Pruc, Dorota Jablonska-Moczulo et al.

Background/Objectives: Treatment-resistant depression (TRD) is heterogeneous and recurrent. Psilocybin administered with structured psychological support can reduce symptoms rapidly. Support protocols differ in content and intensity, and trial design complicates estimates of the specific drug effect and durability. We reviewed efficacy, durability, mechanisms, safety, and clinical delivery in...

DOI: 10.3390/therapeutics3040021 (opens in new tab)

The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review

Current Neuropharmacology October 14, 2026 Mareli Vázquez-Barreto, Mariana Ugarte-Rocha, Abraham Flores Vargas et al.

Mental disorders are among the leading causes of non-fatal health loss worldwide and are associated with significant individual, social, and economic burdens. On the other hand, neuropathic pain affects approximately 7-8% of the world's adult population and is a leading reason for medical consultations. A bidirectional relationship between depression and pain has been widely documented....

DOI: 10.2174/011570159x513731260923101459 (opens in new tab)

Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.

Psychological Medicine October 6, 2026 Avery Chan Eun, Kevin H. Yang, Joseph J Palamar

Psilocybin use has increased in the US alongside promising therapeutic potential for depression, raising concerns that individuals may forgo conventional mental health treatment for unsupervised psilocybin use. However, no nationally representative studies have examined whether psilocybin use is associated with differential treatment utilization or perceived unmet need for mental health care...

DOI: 10.1017/s0033291726106163 (opens in new tab) Full text (opens in new tab) Depression Psilocybin Unmet need

Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial

Research Square October 5, 2026 Anette Kjellgren, Johan Lundberg, Hampus Yngwe et al. preprint

Abstract Psilocybin treatment has emerged as a promising intervention for Major Depressive Disorder (MDD). However, the contribution of psychotherapeutic support to treatment outcomes remains unclear. This study explored therapists' descriptions of their work during a randomized, double-blind, placebo-controlled psilocybin treatment phase II trial for MDD. Nine therapists participated in...

DOI: 10.21203/rs.3.rs-10879308/v1 (opens in new tab) Full text (opens in new tab)

Psilocybin for Anhedonia in Unipolar and Bipolar Depression: A Systematic Review of Clinical and Preclinical Evidence

Journal of Psychiatric Research October 1, 2026 Erica Kaczmarek, Sabrina Wong, Noah Chisamore et al.

Background Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in MDD, however, its effects on anhedonia specifically have yet to be systematically reviewed. This review evaluates available clinical and pre-clinical research, exploring...

DOI: 10.1016/j.jpsychires.2026.10.023 (opens in new tab)

Clinical trials

All psilocybin for depression trials →